Sight Sciences earnings release, May 6, 2026

Sight Sciences, Inc. (SGHT) · Form 8-K, Item 2.02 · Filed · SEC filing

Sight Sciences Reports First Quarter 2026 Financial Results and

Raises Full Year 2026 Revenue Guidance

MENLO PARK, Calif., May 6, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026.

Recent Financial and Business Highlights

• Generated total revenue of $19.7 million in the first quarter of 2026, an increase of 13% compared to the same period in the prior year.

• Drove Interventional Glaucoma revenue growth of 7% in the first quarter of 2026, with revenue of $18.3 million compared to $17.1 million in the same period in the prior year.

• Attained Interventional Dry Eye revenue of $1.4 million in the first quarter of 2026, representing a 244% increase from the same period in the prior year and an 87% increase from the fourth quarter of 2025.

• Achieved total gross margin of 86% in the first quarter of 2026, flat compared to the same period in the prior year.

• Reduced cash usage to $7.0 million in the first quarter 2026, representing a 40% improvement compared to the same period in the prior year. Cash and cash equivalents totaled $85.0 million as of March 31, 2026.

• Announced that the U.S. District Court for the District of Delaware issued its final judgment on post-trial motions in the Company’s patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon), preserving the jury’s verdict of willful infringement and awarding the Company past monetary damages of $55.4 million and an ongoing royalty of 10% of Hydrus® Microstent revenue through expiration of the patents-in-suit. This judgment is subject to appeal.

“We delivered a strong start to 2026, with first quarter results reflecting a return to double-digit revenue growth, sustained gross margin strength, and disciplined operating expense and cash management,” said Paul Badawi, Co-Founder and CEO of Sight Sciences. “Execution was solid across both segments, including a third consecutive quarter of revenue growth in Interventional Glaucoma and continued momentum in Interventional Dry Eye, where revenue nearly doubled sequentially. We remain focused on continued growth in combination-cataract procedures and activating standalone interventions in glaucoma, and accelerating growth and expanding access to reimbursed interventional TearCare® treatments.”

First Quarter 2026 Financial Results

Revenue for the first quarter of 2026 was $19.7 million, an increase of 13% compared to the same period in the prior year. Interventional Glaucoma revenue was $18.3 million, an increase of 7% compared to the same period in the prior year. This improvement was primarily driven by an increase in both ordering accounts and average selling prices, slightly offset by lower utilization per account. Interventional Dry Eye revenue was $1.4 million, increasing from $0.4 million in the same period in the prior year, primarily due to increased average selling prices, utilization and ordering accounts.

Gross profit for the first quarter of 2026 was $17.0 million compared to $15.1 million in the same period in the prior year. Gross margin for the first quarter of 2026 was 86%, flat compared to the same period in the prior year. Interventional Glaucoma gross margin in the first quarter of 2026 was 87%, in line with the same period in the prior year, primarily due to higher average selling prices and product mix, offset by increased tariff expense. Interventional Dry Eye gross margin in the first quarter of 2026 was 72%, up from 71% in the same period in the prior year, primarily due to higher average selling prices and increased SmartLids sold, mostly offset by a one-time inventory overhead adjustment in the prior year period.

Total operating expenses were $29.4 million in the first quarter of 2026, representing a 2% increase compared to $29.0 million in the same period in the prior year, primarily due to a $5.4 million one-time success fee associated with the final judgment in the Alcon litigation, partially offset by lower personnel-related expenses and stock-based compensation. Research and development expenses were $2.5 million in the first quarter of 2026 compared to $4.4 million in the same period in the prior year, representing a 43% decrease. Selling, general, and administrative expenses were $26.8 million in the first quarter of 2026, compared to $24.5 million in the same period in the prior year, representing a 9% increase. Adjusted operating expenses

1,2 were $21.2 million in the first quarter of 2026, a 14% decrease compared to the period in the prior year.

Net loss was $13.0 million, or a loss of $0.24 per share, in the first quarter of 2026, compared to a net loss of $14.2 million, or a loss of $0.28 per share, in the same period in the prior year.

Cash and cash equivalents totaled $85.0 million and total long-term debt was $40.0 million (before debt discount and amortized debt issuance costs) as of March 31, 2026, compared to $92.0 million and $40.0 million, respectively, as of December 31, 2025. Cash used in the first quarter of 2026 totaled $7.0 million, a significant decrease compared to $11.6 million in the first quarter of 2025.

2026 Financial Guidance

Sight Sciences raises its revenue guidance for full year 2026 to range from $83.0 million to $89.0 million, representing growth of 7% to 15% compared to full year 2025,... (truncated) million to $8.0 million, compared to $1.6 million in 2025.

The Company reaffirms its full year 2026 adjusted operating expenses

1,3 guidance range of $93.0 million to $96.0 million, representing an increase of 6% to 9% compared to 2025. The increase compared to the prior year is primarily due to targeted investments in both business segments, including expanded market access efforts and additional commercial resources to scale the reimbursed dry eye market and the standalone glaucoma opportunity.¹

“

Adjusted operating expenses” is a financial measure not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”, and therefore such a measure, is a “non-GAAP financial measure”), and is calculated as operating expenses less stock-based compensation expense, depreciation and amortization, restructuring costs, and other one-time costs. Please see the “Non-GAAP Financial Measures” section below for additional information.²

A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures has been provided in the table titled "Non-GAAP to GAAP Reconciliation" attached to this press release.³

Consistent with Securities and Exchange Commission (“SEC”) regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.

Non-GAAP Financial Measures

Adjusted operating expenses, a non-GAAP financial measure, is presented in this press release to provide information that may assist investors in understanding the Company's financial and operating results. The Company believes this non-GAAP financial measure is an important performance indicator because it excludes items that are unrelated to, and may not be indicative of, the Company's core financial and operating results. This non-GAAP financial measure, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be an appropriate measure for comparing the performance of other companies relative to the Company. This non-GAAP financial measure is not intended to represent, and should not be considered to be a more meaningful measure than, or an alternative to, measures of operating performance as determined in accordance with GAAP. To the extent the Company utilizes such non-GAAP financial measure in the future, it expects to calculate it using a consistent method from period to period.

Conference Call

Sight Sciences' management team will host a conference call today, May 6, 2026, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section.

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s

OMNI® Surgical System and

OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The

SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s

TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.

Sight Sciences, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI, SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories.

Hydrus® is a registered trademark of Alcon Vision LLC.

© 2026 Sight Sciences. All rights reserved.

Financial statements

Income Statement

Three Months Ended March 31, — a) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue19,69817,508
Cost of goods sold2,7202,414
Gross profit16,97815,094
Operating expenses:Research and development2,5464,430
Operating expenses:Selling, general and administrative26,84524,523
Operating expenses:Total operating expenses29,39128,953
Operating expenses:Loss from operations-12,413-13,859
Operating expenses:Investment income7411,148
Operating expenses:Interest expense-1,268-1,263
Operating expenses:Other expense, net-29-139
Operating expenses:Loss before income taxes-12,969-14,113
Operating expenses:Provision for income taxes1141
Operating expenses:Net loss and comprehensive loss-12,980-14,154
Operating expenses:Net loss per share attributable to common stockholders, basic and diluted-0.24-0.28
Operating expenses:Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted53,943,08551,290,665

Income Statement

Three Months Ended March 31, — (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenueSurgical Glaucoma18,34417,114
RevenueDry Eye1,354394
RevenueTotal revenue19,69817,508
Cost of goods soldSurgical Glaucoma2,3422,298
Cost of goods soldDry Eye378116
Cost of goods soldTotal cost of goods sold2,7202,414
Gross profitSurgical Glaucoma16,00214,816
Gross profitDry Eye976278
Gross profitTotal gross profit16,97815,094
Gross marginSurgical Glaucoma87.2%86.6
Gross marginDry Eye72.1%70.6
Gross marginTotal gross margin86.2%86.2

Balance Sheet

December 31, — (in thousands, except share and per share data)

March 31, – 2026December 31, – 2025
Current assets:Cash and cash equivalents84,96291,965
Current assets:Accounts receivable, net of allowance for credit losses of $139 and $234 at March 31, 2026 and December 31, 2025, respectively10,5959,745
Current assets:Inventory, net7,0077,767
Current assets:Prepaid expenses and other current assets3,9483,257
Current assets:Total current assets106,512112,734
Current assets:Property and equipment, net1,6181,610
Current assets:Operating lease right-of-use assets1,202438
Current assets:Other noncurrent assets370518
Current assets:Total assets109,702115,300
Current liabilities:Accounts payable1,4861,343
Current liabilities:Accrued compensation3,6916,074
Current liabilities:Accrued and other current liabilities9,1893,610
Current liabilities:Short-term debt, net3,797
Current liabilities:Total current liabilities18,16311,027
Current liabilities:Long-term debt, net36,73640,300
Current liabilities:Other noncurrent liabilities90031
Current liabilities:Total liabilities55,79951,358
Stockholders’ equity:Common stock, par value $0.001 per share; 200,000,000 shares authorized; 54,033,998 and 53,493,711 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5454
Stockholders’ equity:Additional paid-in-capital451,552448,611
Stockholders’ equity:Accumulated deficit-397,703-384,723
Stockholders’ equity:Total stockholders’ equity53,90363,942
Stockholders’ equity:Total liabilities and stockholders’ equity109,702115,300
Full release

Forward-Looking Statements... (truncated)ng royalties in our ongoing litigation with Alcon; potential appeals or other post-judgment proceedings; our focus in 2026 on continued growth in combination-cataract procedures and activating standalone interventions in glaucoma, and accelerating growth and expanding access to reimbursed interventional TearCare treatments; 2026 revenue guidance and 2026 adjusted operating expenses guidance, including primary factors impacting this guidance.

These statements often include words such as "anticipate," "expect," “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition, including without limitation changes to reimbursement coverage or payment decisions or reimbursement rates for our products; pricing pressure or changes in market share resulting from the evolving competitive landscape; the impact of tariffs on our products and the medical device industry generally; and disruptions to or increased costs associated with our supply chain, including as a result of having a limited number of suppliers. Should our underlying assumptions prove incorrect, actual results may differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the SEC, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor contact:

Philip Taylor

Gilmartin Group

415.937.5406

Investor.Relations@Sightsciences.com

Media contact: pr@SightSciences.com

SIGHT SCIENCES, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)

SIGHT SCIENCES, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share dat a)

SIGHT SCIENCES, INC.

Gross Margin Disaggregation (Unaudited)

(in thousands)

SIGHT SCIENCES, INC.

GAAP to Non-GAAP Reconciliation (Unaudited)

(in thousands)⁴

Please see section titled "Non-GAAP Financial Measures" for additional information.

SIGHT SCIENCES, INC.

Supplemental Financial Measures (Unaudited)⁵

“Interventional Glaucoma active customers” means the number of customers who ordered the OMNI Surgical System or the SION Surgical Instrument during the three months ended March 31, 2026 and 2025.⁶

“Interventional Dry Eye lid treatment units sold” means the quantity of TearCare SmartLids® sold during the three months ended March 31, 2026 and 2025.⁷

“

Interventional Dry Eye active customers” means the number of customers who ordered lid treatment units during the three months ended March 31, 2026 and 2025.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Sight Sciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.